Literature DB >> 24142682

Long-term follow-up after pacemaker implantation via persistent left superior vena cava.

Paweł Dąbrowski1, Bogdan Obszański, Andrzej Kleinrok, Andrzej Kutarski.   

Abstract

BACKGROUND: The persistent left superior vena cava (PLSVC) is a relatively common con-genital venous return anomaly. It may have serious clinical implications especially in case of pacemaker/cardioverter-defibrillator implantation, venous catheter insertion, radio-frequency ablation and cardiac surgery. There is also some evidence that PLSVC may be accompanied by arrhythmias. The aim of this report is to present the effectiveness and safety of cardiac pacing via PLSVC, clinical outcome and appearance of arrhythmias in a long-term follow-up. METHODS AND
RESULTS: Four cases of pacing electrodes implanted via PLSVC in patients without any other cardiac congenital heart anomalies were observed for at least 6 years. There was 1 patient with AAI, 2 patients with VVI, and 1 with DDD pacemaker. Atrial electrodes were implanted on the free right atrial wall, 2 ventricular electrodes were implanted in right ventricular outflow tract, 1 in postero-lateral cardiac vein. During the mean 110 months of observation, pacing was efficient. One patient underwent an upgrade from AAI to biatrial pac-ing due to progressive interatrial conduction delay during the follow-up. No other intervention or pacemaker related events were noticed except for battery replacement.
CONCLUSIONS: The presence of PSVC may complicate implantation, but it does not influence the long-term follow-up of pacing parameters.

Entities:  

Mesh:

Year:  2013        PMID: 24142682     DOI: 10.5603/CJ.a2013.0145

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  1 in total

1.  Transvenous dual-chamber pacemaker implantation in patients with persistent left superior vena cava.

Authors:  Teng Li; Qiong Xu; Hong-Tao Liao; Dimitrios Asvestas; Konstantinos P Letsas; Yifu Li
Journal:  BMC Cardiovasc Disord       Date:  2019-04-29       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.